CLINICAL ROLE -
Britny Brown, PharmD, BCOP, discusses the importance of the NCCN guidelines in the treatment of metastatic breast cancer (mBC) and explains how the NCCN recommendations for CDK4/6 inhibitors differ for first-line patients.
Genetic Insights in Taxane-Related Nerve Damage for Breast Cancer Survivors
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
T-DXd New Standard of Care Following ET in HER2-Low, -Ultralow HR+ Metastatic Breast Cancer
Pharmacy Focus: Oncology Edition - Breast Cancer Treatments Are Rapidly Expanding
FDA Grants Inavolisib Priority Review for Treatment of PIK3CA-Mutated Breast Cancer
Breast Cancer Endocrine Therapy Nonpersistence, Nonadherence Associated With Socioeconomic and Behavioral Factors